Hemophilia A Treatment Gets Green Light
The US Food and Drug Administration (FDA) has approved a new treatment for hemophilia A.
Another Hemophilia Treatment Option
Patients with hemophilia B, a rare, inherited bleeding disorder, may soon have another treatment option.
New Recommendations for Hemophilia Patients
The National Hemophilia Foundation (NHF) recently issued a new recommendation on inhibitor testing for patients with hemophilia A and B.
Modified Hemophilia Rx Approved
The U.S. Food and Drug Administration today approved Adynovate, Antihemophilic Factor (Recombinant), PEGylated for use in adults and adolescents, aged 12 years and older, who have Hemophilia A.
FDA Approves Rx for Rare Type of Hemophilia
The US Food and Drug Administration (FDA) approved a new treatment Thursday for a rare form of hemophilia.
FDA Approves New Treatment for Rare Form of Hemophilia
The U.S. Food and Drug Administration yesterday approved Obizur [Antihemophilic Factor (Recombinant), Porcine Sequence] for the treatment of bleeding episodes in adults with acquired hemophilia A (acquired Factor VIII [FVII] deficiency).
FDA Approves Alprolix for Patients With Hemophilia B
The U.S. Food and Drug Administration today approved Alprolix, Coagulation Factor IX (Recombinant), Fc Fusion Protein, for use in adults and children who have Hemophilia B. Alprolix is the first Hemophilia B treatment designed to require less frequent injections when used to prevent or reduce the frequency of bleeding.
Rare Diseases You've Never Heard Of
In an effort to help raise awareness about rare diseases, here is an introduction to several rare conditions you might not know existed.
FDA Approves First Recombinant Coagulation Factor IX
The US Food and Drug Administration yesterday approved Rixubis [Coagulation Factor IX (Recombinant)] for use in people with hemophilia B who are 16 years of age and older.
Potential Hemophilia B Cure Unveiled
A novel one-time intravenous gene therapy infusion could potentially cure patients with severe hemophilia B. Four patients from the small trial have had such success that they have discontinued traditional treatment.